BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
Number Citing Articles
1 Kochar B, Jiang Y, Winn A, Barnes EL, Martin CF, Long MD, Kappelman MD. The Early Experience With Vedolizumab in the United States. Crohns Colitis 360 2019;1:otz027. [PMID: 31667469 DOI: 10.1093/crocol/otz027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Weaver KN, Long MD. Preventive Medicine in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019;17:824-8. [PMID: 30529728 DOI: 10.1016/j.cgh.2018.11.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Friedman S. A Meta-analysis of Sexual Function in Patients With Inflammatory Bowel Disease: Examining a Small Piece of the Puzzle. Inflamm Bowel Dis 2019;25:708-10. [PMID: 30476086 DOI: 10.1093/ibd/izy348] [Reference Citation Analysis]
4 Barreiro-De Acosta M, Domènech E, Martín Arranz MD, García Sánchez V, Gutiérrez Casbas A, Chaparro M, Alcain G, Iborra M, Taxonera C, Rodriguez-Lago I, Menchén L, Khorrami S, Romero C, Cea-Calvo L, Juliá B. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. Expert Rev Gastroenterol Hepatol 2019;13:807-13. [PMID: 31203691 DOI: 10.1080/17474124.2019.1626717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Steiner CA, Berinstein JA, Louissaint J, Higgins PDR, Spence JR, Shannon C, Lu C, Stidham RW, Fletcher JG, Bruining DH, Feagan BG, Jairath V, Baker ME, Bettenworth D, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00593-0. [PMID: 34089850 DOI: 10.1016/j.cgh.2021.05.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Niu M, Chen Z, Li M, Zhang X, Chen C, Rufo PA. Differentiation of Isolated Small Bowel Crohn’s Disease from Other Small Bowel Ulcerative Diseases: Clinical Features and Double-Balloon Enteroscopy Characteristics. Gastroenterology Research and Practice 2022;2022:1-13. [DOI: 10.1155/2022/5374780] [Reference Citation Analysis]
7 Yang QY, Liu YJ, Xu Y, Zhang L, Wang CD. Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease. J Dig Dis 2021;22:473-80. [PMID: 34240823 DOI: 10.1111/1751-2980.13032] [Reference Citation Analysis]
8 Bolwell JG, Wild D. Indications, Contraindications, and Considerations for Video Capsule Endoscopy. Gastrointest Endosc Clin N Am 2021;31:267-76. [PMID: 33743925 DOI: 10.1016/j.giec.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lu TX, Dapas M, Lin E, Peters T, Sakuraba A. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut 2021;70:2076-84. [PMID: 33334900 DOI: 10.1136/gutjnl-2020-321609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Honap S, Johnston E, Agrawal G, Al-Hakim B, Hermon-Taylor J, Sanderson J. Anti-Mycobacterium paratuberculosis (MAP) therapy for Crohn's disease: an overview and update. Frontline Gastroenterol 2021;12:397-403. [PMID: 35401965 DOI: 10.1136/flgastro-2020-101471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
12 Sheriff MZ, Mansoor E, Luther J, Ananthakrishnan AN, Abou Saleh M, Ho E, Briggs FBS, Dave M. Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study. Inflamm Bowel Dis 2020;26:291-300. [PMID: 31314891 DOI: 10.1093/ibd/izz147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yee J, Kim SM, Han JM, Lee N, Yoon HY, Gwak HS. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep 2020;10:3658. [PMID: 32107440 DOI: 10.1038/s41598-020-60467-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gade AK, Douthit NT, Townsley E. Medical Management of Crohn's Disease. Cureus. 2020;12:e8351. [PMID: 32617224 DOI: 10.7759/cureus.8351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Nocerino A, Nguyen A, Agrawal M, Mone A, Lakhani K, Swaminath A. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. Adv Ther 2020;37:97-112. [PMID: 31760611 DOI: 10.1007/s12325-019-01151-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
18 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis 2021;27:1346-55. [PMID: 33051647 DOI: 10.1093/ibd/izaa265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
21 Curtin JM, Aronson NE. Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity. Microorganisms 2021;9:578. [PMID: 33799892 DOI: 10.3390/microorganisms9030578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Schots L, Grine L, Soenen R, Lambert J. Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. J Dermatolog Treat 2020;:1-9. [PMID: 33019835 DOI: 10.1080/09546634.2020.1832649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Ford MM. Crohn's Disease Obstructions. Clin Colon Rectal Surg 2021;34:227-32. [PMID: 34305471 DOI: 10.1055/s-0041-1729926] [Reference Citation Analysis]
24 Goold E, Pearson L, Johnson LM. Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants? Clin Biochem 2020;84:51-4. [PMID: 32628920 DOI: 10.1016/j.clinbiochem.2020.06.015] [Reference Citation Analysis]
25 Kim SB, Cheon JH, Park JJ, Kim ES, Jeon SW, Jung SA, Park DI, Lee CK, Im JP, Kim YS, Kim HS, Lee J, Eun CS, Lee JM, Jang BI, Seo GS. Risk Factors for Postoperative Recurrence in Korean Patients with Crohn's Disease. Gut Liver 2020;14:331-7. [PMID: 31550869 DOI: 10.5009/gnl19085] [Reference Citation Analysis]
26 Reed CC, Iglesia EGA, Commins SP, Dellon ES. Seasonal exacerbation of eosinophilic esophagitis histologic activity in adults and children implicates role of aeroallergens. Ann Allergy Asthma Immunol 2019;122:296-301. [PMID: 30578860 DOI: 10.1016/j.anai.2018.12.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
27 Weissman S, Sinh P, Mehta TI, Thaker RK, Derman A, Heiberger C, Qureshi N, Amrutiya V, Atoot A, Dave M, Tabibian JH. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol 2020; 11(5): 104-113 [PMID: 32832194 DOI: 10.4291/wjgp.v11.i5.104] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Yang T, Cui X, Tang M, Qi W, Zhu Z, Shi M, Yang L, Pei H, Zhang W, Xie L, Xu Y, Yang Z, Chen L. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2022. [PMID: 35113547 DOI: 10.1021/acs.jmedchem.1c01137] [Reference Citation Analysis]
29 Berinstein JA, Steiner CA, Bousvaros A, Tiongco FP, Greenberg E, Hardi R, Lembo AJ, Friedenberg K, Sedghi S, Fint A, Florez DA, Kumar A, Arsenescu R, Park KT, Kupchak P, Grob A, Leavitt J, Higgins PDR. The Clinical Accuracy of the BÜHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case–Control Study. Crohn's & Colitis 360 2019;1:otz037. [DOI: 10.1093/crocol/otz037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Agboton C, Salameh J. Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe. Expert Opin Biol Ther 2021;:1-11. [PMID: 34338115 DOI: 10.1080/14712598.2021.1963435] [Reference Citation Analysis]
31 Lee J, Lemons N, Lorenze A, Chowdhary TS, Zinn Z, Gayam S. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. J Gastroenterol Hepatol 2021. [PMID: 34139789 DOI: 10.1111/jgh.15570] [Reference Citation Analysis]
32 Rodriguez-Palacios A, Basson AR, Cominelli F. Artificial Sweeteners and Whole-Food Science: Could Mice Help Clinicians Make Diet Recommendations for IBD Patients? Gastroenterology 2021;161:8-14. [PMID: 33798527 DOI: 10.1053/j.gastro.2021.03.041] [Reference Citation Analysis]
33 Dines JT, Harvey A. Chronic intentional chicken bone ingestion mimicking inflammatory bowel disease. BMJ Case Rep 2021;14:e239022. [PMID: 34088681 DOI: 10.1136/bcr-2020-239022] [Reference Citation Analysis]
34 Statie RC, Florescu DN, Gheonea DI, Ciurea T. Rare Complication During Anti-TNF-α Treatment in a Patient with Crohn's Disease: A Case Report and Review of the Literature. Curr Health Sci J 2021;47:132-8. [PMID: 34211761 DOI: 10.12865/CHSJ.47.01.22] [Reference Citation Analysis]
35 Click B, Barnes EL, Cohen BL, Sands BE, Hanson JS, Rubin DT, Dubinsky MC, Regueiro M, Gazis D, Crawford JM, Long MD. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02143-x] [Reference Citation Analysis]
36 Weber AT, Shah ND, Sauk J, Limketkai BN. Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence. Curr Treat Options Gastroenterol 2019;17:564-76. [PMID: 31705371 DOI: 10.1007/s11938-019-00248-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc 2019;90:269-75. [PMID: 30738034 DOI: 10.1016/j.gie.2019.01.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
38 Agrawal M, Kim ES, Colombel JF. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. J Crohns Colitis 2020;14:S755-60. [PMID: 32006031 DOI: 10.1093/ecco-jcc/jjaa017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
39 Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol 2021;14:17562848211023399. [PMID: 34276809 DOI: 10.1177/17562848211023399] [Reference Citation Analysis]
40 Higashijima J, Kono T, Shimada M, Kashihara H, Takasu C, Nishi M, Tokunaga T, Sugitani A, Yoshikawa K. Intestinal hypoperfusion in patients with Crohn's disease revealed by intraoperative indocyanine green fluorescence imaging. Ann Med Surg (Lond) 2021;66:102402. [PMID: 34136203 DOI: 10.1016/j.amsu.2021.102402] [Reference Citation Analysis]
41 Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin 2019;35:1751-9. [PMID: 31106607 DOI: 10.1080/03007995.2019.1620713] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
42 Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB. Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2020;26:1808-18. [PMID: 32064534 DOI: 10.1093/ibd/izaa031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Kuenstner L, Kuenstner JT. Mycobacterium avium ssp. paratuberculosis in the Food Supply: A Public Health Issue. Front Public Health 2021;9:647448. [PMID: 34336758 DOI: 10.3389/fpubh.2021.647448] [Reference Citation Analysis]
45 Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract 2021;:e14365. [PMID: 34008296 DOI: 10.1111/ijcp.14365] [Reference Citation Analysis]
46 Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. Ann Surg 2021;273:557-63. [PMID: 31188225 DOI: 10.1097/SLA.0000000000003395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
47 Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. Adv Ther 2021;38:2586-98. [PMID: 33844132 DOI: 10.1007/s12325-021-01713-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL. Patient and general population values for luminal and perianal fistulising Crohn's disease health states. Eur J Health Econ 2019;20:91-100. [PMID: 31102158 DOI: 10.1007/s10198-019-01065-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Zingel R, Bohlken J, Kostev K. Association Between Inflammatory Bowel Disease and Dementia: A Retrospective Cohort Study. J Alzheimers Dis 2021;80:1471-8. [PMID: 33720902 DOI: 10.3233/JAD-210103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
51 Wan J, Wang X, Zhang Y, Xue X, Li Y, Liu Z, Han S, Chen M, Nie Y, Shi Y, Liang J, Wu K. 5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study. Can J Gastroenterol Hepatol 2021;2021:1412663. [PMID: 34422708 DOI: 10.1155/2021/1412663] [Reference Citation Analysis]
52 Yerushalmy-Feler A, Assa A. Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn's Disease. Paediatr Drugs 2019;21:451-60. [PMID: 31628665 DOI: 10.1007/s40272-019-00361-7] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther 2022;39:2065-84. [PMID: 35287231 DOI: 10.1007/s12325-022-02098-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Henry C, Bassignani A, Berland M, Langella O, Sokol H, Juste C. Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers—Example of Crohn’s Disease and Ulcerative Colitis Flare-Ups. Cells 2022;11:1340. [DOI: 10.3390/cells11081340] [Reference Citation Analysis]
55 Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145:16-27. [PMID: 31910984 DOI: 10.1016/j.jaci.2019.11.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 36.5] [Reference Citation Analysis]
56 Mir A, Nguyen VQ, Soliman Y, Sorrentino D. Wireless Capsule Endoscopy for Diagnosis and Management of Post-Operative Recurrence of Crohn's Disease. Life (Basel) 2021;11:602. [PMID: 34201514 DOI: 10.3390/life11070602] [Reference Citation Analysis]
57 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Lucafò M, Franzin M, Lagatolla C, Franca R, Bramuzzo M, Stocco G, Decorti G. Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci 2020;13:238-59. [PMID: 31675176 DOI: 10.1111/cts.12722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. J Med Econ 2020;23:1092-101. [PMID: 32609019 DOI: 10.1080/13696998.2020.1789649] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ye C, Zhu S, Yuan J. Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease. Front Immunol 2022;13:871312. [DOI: 10.3389/fimmu.2022.871312] [Reference Citation Analysis]
61 Sun DJ, Li HT, Ye Z, Xu BB, Li DZ, Wang W. Gastrointestinal bleeding caused by syphilis: A case report. World J Clin Cases 2021; 9(26): 7909-7916 [PMID: 34621845 DOI: 10.12998/wjcc.v9.i26.7909] [Reference Citation Analysis]
62 Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. J Crohns Colitis 2021:jjab093. [PMID: 34077509 DOI: 10.1093/ecco-jcc/jjab093] [Reference Citation Analysis]
63 Chiu Y, Chen C, Ko C, Liao S, Yeh H, Chang C. Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. Adv in Digestive Med 2021;8:40-6. [DOI: 10.1002/aid2.13188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
64 Agrawal G, Clancy A, Huynh R, Borody T. Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series. Gut Pathog. 2020;12:16. [PMID: 32308741 DOI: 10.1186/s13099-020-00355-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
65 Stidham RW, Takenaka K. Artificial Intelligence for Disease Assessment in IBD: How Will it Change Our Practice? Gastroenterology 2022:S0016-5085(21)04070-1. [PMID: 34995537 DOI: 10.1053/j.gastro.2021.12.238] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Noureldin M, Cohen-Mekelburg S, Mahmood A, Stidham R, Higgins PDR, Govani S, Deshpande AR, Waljee AK. Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease. Inflamm Bowel Dis 2021;27:516-21. [PMID: 32469067 DOI: 10.1093/ibd/izaa127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Batra S, Conklin LS. Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm. Handb Exp Pharmacol 2020;261:363-75. [PMID: 31342277 DOI: 10.1007/164_2019_255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Stoner PL, Kamel A, Ayoub F, Tan S, Iqbal A, Glover SC, Zimmermann EM. Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support. Gastroenterol Res Pract. 2018;2018:7890161. [PMID: 30344603 DOI: 10.1155/2018/7890161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
69 Rolak S, Kane SV. Conventional Therapies for Crohn's Disease. Gastroenterol Clin North Am 2022;51:271-82. [PMID: 35595414 DOI: 10.1016/j.gtc.2021.12.004] [Reference Citation Analysis]
70 Kumar A, Lukin DJ. Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2020;32:205-15. [PMID: 31851091 DOI: 10.1097/MEG.0000000000001648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, Lewis JD. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:2082-2092.e10. [DOI: 10.1016/j.cgh.2020.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00344-X. [PMID: 33798711 DOI: 10.1016/j.cgh.2021.03.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
73 Stilwell KT, Estes J, Kurtz MT, Francis JM, Lynch DT, Patel AA. CMV Ileitis: To Treat or Not to Treat? Implications of Initiating Biologic Therapy for Concurrent Crohn's Disease. Case Rep Gastrointest Med 2019;2019:4513795. [PMID: 31321105 DOI: 10.1155/2019/4513795] [Reference Citation Analysis]
74 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
75 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
76 Grossberg LB, Farraye FA, Papamichael K, Cheifetz AS, Feuerstein JD. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis 2020;26:e59-61. [PMID: 32304571 DOI: 10.1093/ibd/izaa079] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Lobo A, Torrejon Torres R, McAlindon M, Panter S, Leonard C, van Lent N, Saunders R. Economic analysis of the adoption of capsule endoscopy within the British NHS. Int J Qual Health Care 2020;32:332-41. [PMID: 32395758 DOI: 10.1093/intqhc/mzaa039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
79 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol. 2020;55:291-306. [PMID: 31836930 DOI: 10.1007/s00535-019-01647-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
81 Lin L, Wyness SP, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM. Comparison of Next-Generation Assays for Fecal Calprotectin vs the PhiCal Assay. Am J Clin Pathol 2022;157:252-6. [PMID: 34390332 DOI: 10.1093/ajcp/aqab114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology 2019;157:1032-1043.e1. [PMID: 31228441 DOI: 10.1053/j.gastro.2019.06.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
85 Caldera F, Ley D, Hayney MS, Farraye FA. Optimizing Immunization Strategies in Patients with IBD.Inflamm Bowel Dis. 2021;27:123-133. [PMID: 32232388 DOI: 10.1093/ibd/izaa055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
86 Gallego JC, de Juan C, Echarri A, Lopez-de-ullibarri I. Small-Bowel Crohn Disease Treated With Anti–Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes. American Journal of Roentgenology 2019;213:1240-6. [DOI: 10.2214/ajr.19.21186] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Hong Q, Shen J, Feng Q, Zheng Q, Qiao Y. Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease. BMC Gastroenterol 2022;22:183. [PMID: 35413806 DOI: 10.1186/s12876-022-02238-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Cushing K, Higgins PDR. Management of Crohn Disease: A Review. JAMA 2021;325:69-80. [PMID: 33399844 DOI: 10.1001/jama.2020.18936] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 38.0] [Reference Citation Analysis]
89 Tetangco EP, Stein AC. Medical Treatment of Intestinal Crohn's disease. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100862] [Reference Citation Analysis]
90 Peng Z, Xu D, Li Y, Peng Y, Liu X. Phase Angle as a Comprehensive Tool for Nutritional Monitoring and Management in Patients with Crohn’s Disease. Nutrients 2022;14:2260. [DOI: 10.3390/nu14112260] [Reference Citation Analysis]
91 Hong SJ, Galati J, Katz S. Crohn's Disease of the Elderly. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.014] [Reference Citation Analysis]
92 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
93 Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022;22:291. [PMID: 35676620 DOI: 10.1186/s12876-022-02347-1] [Reference Citation Analysis]
94 Gupta S, Allegretti JR. Mimics of Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.006] [Reference Citation Analysis]
95 Grillo TG, Quaglio AEV, Beraldo RF, Lima TB, Baima JP, Di Stasi LC, Sassaki LY. MicroRNA expression in inflammatory bowel disease-associated colorectal cancer. World J Gastrointest Oncol 2021; 13(9): 995-1016 [PMID: 34616508 DOI: 10.4251/wjgo.v13.i9.995] [Reference Citation Analysis]
96 Both T, Dalm VASH, Richardson SA, van Schie N, van den Broek LM, de Vries AC, van Hagen PM, Rombach SM. Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review. Autoimmun Rev 2021;20:102872. [PMID: 34118459 DOI: 10.1016/j.autrev.2021.102872] [Reference Citation Analysis]
97 Kondo A, Ma S, Lee MYY, Ortiz V, Traum D, Schug J, Wilkins B, Terry NA, Lee H, Kaestner KH. Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease. Gastroenterology 2021:S0016-5085(21)03480-6. [PMID: 34529988 DOI: 10.1053/j.gastro.2021.08.055] [Reference Citation Analysis]
98 Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn’s Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0687-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Brady JE, Stott-miller M, Mu G, Perera S. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. Clinical Therapeutics 2018;40:1509-1521.e5. [DOI: 10.1016/j.clinthera.2018.07.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Chang HC, Chen G, Chung HW, Wu PY, Liang L, Juan CJ, Liu YJ, Tse MD, Chan A, Zhang S, Chiu KW. Multi-shot Diffusion-Weighted MRI With Multiplexed Sensitivity Encoding (MUSE) in the Assessment of Active Inflammation in Crohn's Disease. J Magn Reson Imaging 2021. [PMID: 34169600 DOI: 10.1002/jmri.27801] [Reference Citation Analysis]
101 Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol 2020;4:16. [PMID: 32266326 DOI: 10.1186/s41927-020-0115-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
102 Karpin J, Rodriguez TG, Traboulsi C, Rai V, Gibbons RD, Rubin DT. Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. Crohns Colitis 360 2021;3:otaa095. [PMID: 34746788 DOI: 10.1093/crocol/otaa095] [Reference Citation Analysis]
103 Orr MR, Kocurek KM, Bakos YJ, McDowell RC. A restoration ecology perspective on the treatment of inflammatory bowel disease. Evol Med Public Health 2019;2019:217-20. [PMID: 31857899 DOI: 10.1093/emph/eoz031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Jain SR, Ow ZGW, Chin YH, Lim WH, Kong G, Tham HY, Wong NW, Chong CS, Foo FJ, Chan WPW. Quantifying the rate of recurrence of postoperative Crohn's disease with biological therapy. A meta-analysis. J Dig Dis 2021;22:399-407. [PMID: 34048153 DOI: 10.1111/1751-2980.13025] [Reference Citation Analysis]
105 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Ungaro RC, Hu L, Ji J, Nayar S, Kugathasan S, Denson LA, Hyams J, Dubinsky MC, Sands BE, Cho JH. Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. Aliment Pharmacol Ther 2021;53:281-90. [PMID: 33131065 DOI: 10.1111/apt.16136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Dane B, Garada A, O'Donnell T, Chang S, Megibow A. Crohn Disease Prognostication With Semiautomatic Dual-Energy Computed Tomography Enterography-Derived Iodine Density. J Comput Assist Tomogr 2021;45:171-6. [PMID: 33661155 DOI: 10.1097/RCT.0000000000001135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kassel L, Hutton A, Zumach G, Rand J. Systematic review of perioperative use of immunosuppressive agents in patients undergoing bariatric surgery. Surg Obes Relat Dis 2020;16:144-57. [PMID: 31735569 DOI: 10.1016/j.soard.2019.10.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:155-61. [PMID: 33089863 DOI: 10.1093/ibd/izaa278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
110 Limketkai BN, Gordon M, Mutlu EA, De Silva PS, Lewis JD. Diet Therapy for Inflammatory Bowel Diseases: A Call to the Dining Table. Inflamm Bowel Dis 2020;26:510-4. [PMID: 31819987 DOI: 10.1093/ibd/izz297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
111 Lei H, Crawford MS, McCole DF. JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:840. [PMID: 34577540 DOI: 10.3390/ph14090840] [Reference Citation Analysis]
112 Stojsavljević A, Sokić-Milutinović A, Rovčanin B, Tončev L, Manojlović D. Profiling of Circulatory Elements Reveals Alteration of Essential and Toxic Trace Metals in Crohn's Disease. Biol Trace Elem Res 2021. [PMID: 34357515 DOI: 10.1007/s12011-021-02862-4] [Reference Citation Analysis]
113 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-Gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M; en representación de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. Gastroenterol Hepatol 2021:S0210-5705(21)00219-3. [PMID: 34274357 DOI: 10.1016/j.gastrohep.2021.07.001] [Reference Citation Analysis]
114 Yu RG, Zhang JY, Liu ZT, Zhuo YG, Wang HY, Ye J, Liu N, Zhang YY. Text Mining-Based Drug Discovery in Osteoarthritis. J Healthc Eng 2021;2021:6674744. [PMID: 33953899 DOI: 10.1155/2021/6674744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Villanacci V, Reggiani-Bonetti L, Caprioli F, Saragoni L, Salviato T, Mescoli C, Canavese G, Manenti S, Spada E, Baron L, Leoncini G, Cadei M, Battista S, Armuzzi A. Histopathology of inflammatory bowel disease - Position statement of the Pathologists of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Group of Gastrointestinal Pathologists (GIPAD-SIAPEC). Dig Liver Dis 2020;52:262-7. [PMID: 31884010 DOI: 10.1016/j.dld.2019.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
116 Peyrin-Biroulet L, Louis E, Loftus EV Jr, Lacerda A, Zhou Q, Sanchez Gonzalez Y, Ghosh S. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. Adv Ther 2021;38:2339-52. [PMID: 33755884 DOI: 10.1007/s12325-021-01660-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Jansson-Knodell CL, Harris CE, Loftus EV Jr, Walker RC, Enzler MJ, Virk A. Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics? Dig Dis Sci 2021;66:190-8. [PMID: 32144603 DOI: 10.1007/s10620-020-06181-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Monif GRG. Are the permanent sequelae of Crohn's disease a failure to treat the gastrointestinal microbiota? Med Hypotheses 2019;122:198-9. [PMID: 30593411 DOI: 10.1016/j.mehy.2018.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
119 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Gregory MH, McKinnon A, Stwalley D, Hippensteel KJ, Loftus EV Jr, Ciorba MA, Olsen MA, Deepak P. Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. J Crohns Colitis 2019;13:182-8. [PMID: 30256926 DOI: 10.1093/ecco-jcc/jjy148] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
121 Zhang XY, Dong HC, Wang WF, Zhang Y. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World J Gastroenterol 2022; 28(16): 1705-1717 [DOI: 10.3748/wjg.v28.i16.1705] [Reference Citation Analysis]
122 Mckenna NP, Lightner AL. Preoperative Considerations in Inflammatory Bowel Disease. Surgical Clinics of North America 2019;99:1083-94. [DOI: 10.1016/j.suc.2019.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
123 Iheozor-Ejiofor Z, Gordon M, Clegg A, Freeman SC, Gjuladin-Hellon T, MacDonald JK, Akobeng AK. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. Cochrane Database Syst Rev 2019;9:CD013210. [PMID: 31513295 DOI: 10.1002/14651858.CD013210.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
124 Kurowski JA, Achkar JP, Sugano D, Milinovich A, Ji X, Bauman J, Griffin KR, Kattan MW. Computable Phenotype of a Crohn's Disease Natural History Model. Med Decis Making 2022;:272989X221103508. [PMID: 35658747 DOI: 10.1177/0272989X221103508] [Reference Citation Analysis]
125 Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intest Res 2021;19:408-18. [PMID: 33207857 DOI: 10.5217/ir.2020.00025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Vasudevan A, Bruining DH, Loftus EV Jr, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol 2021; 27(25): 3693-3704 [PMID: 34321838 DOI: 10.3748/wjg.v27.i25.3693] [Reference Citation Analysis]
127 Zhang S, Cho WJ, Jin AT, Kok LY, Shi Y, Heller DE, Lee YL, Zhou Y, Xie X, Korzenik JR, Lennerz JK, Traverso G. Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine. Adv Healthc Mater 2020;9:e2000536. [PMID: 32597571 DOI: 10.1002/adhm.202000536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
128 Alipour O, Lee V, Tejura TK, Wilson ML, Memel Z, Cho J, Cologne K, Hwang C, Shao L. The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. Scand J Gastroenterol 2021;:1-7. [PMID: 34344243 DOI: 10.1080/00365521.2021.1958368] [Reference Citation Analysis]
129 Ho EY, Singh S, Terdiman JP. Providing the Best Care for Patients With Crohn's Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2557-62. [PMID: 34051986 DOI: 10.1053/j.gastro.2021.04.024] [Reference Citation Analysis]
130 Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021;160:2340-53. [PMID: 33676969 DOI: 10.1053/j.gastro.2021.02.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Yao L, Zhu X, Shao B, Liu R, Li Z, Wu L, Chen J, Cao Q. Reasons and Factors Contributing to Chinese Patients' Preference for Ustekinumab in Crohn's Disease: A Multicenter Cross-Sectional Study. Front Pharmacol 2021;12:736149. [PMID: 34887751 DOI: 10.3389/fphar.2021.736149] [Reference Citation Analysis]
133 Patel H, Latremouille-viau D, Burne R, Shi S, Adsul S. Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz022. [DOI: 10.1093/crocol/otz022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
134 Grillo TG, Almeida LR, Beraldo RF, Marcondes MB, Queiróz DAR, da Silva DL, Quera R, Baima JP, Saad-Hossne R, Sassaki LY. Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature. World J Clin Cases 2021; 9(33): 10382-10391 [PMID: 34904114 DOI: 10.12998/wjcc.v9.i33.10382] [Reference Citation Analysis]
135 Liu Y, Xu F, Wheaton AG, Greenlund KJ, Thomas CW. The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016. Headache 2021;61:612-9. [PMID: 33756009 DOI: 10.1111/head.14087] [Reference Citation Analysis]
136 Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Jauregui-Amezaga A, Rimola J. Role of Intestinal Ultrasound in the Management of Patients with Inflammatory Bowel Disease. Life (Basel) 2021;11:603. [PMID: 34201630 DOI: 10.3390/life11070603] [Reference Citation Analysis]
139 Barnes EL, Loftus EV Jr, Kappelman MD. Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology 2021;160:677-89. [PMID: 33098884 DOI: 10.1053/j.gastro.2020.08.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
140 Hashash JG, Abou Fadel C, Hosni M, Hassoun L, Kanafani Z, Regueiro MD. Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA? Inflammatory Bowel Diseases 2020;26:1315-8. [DOI: 10.1093/ibd/izaa139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
142 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
143 Shen Z, Sun P, Jiang M, Zhen Z, Liu J, Ye M, Huang W. Endoscopic retrograde appendicitis therapy versus laparoscopic appendectomy versus open appendectomy for acute appendicitis: a pilot study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02139-7] [Reference Citation Analysis]
144 Pelkmans LPJ, de Groot MJM, Curvers J. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. Am J Clin Pathol 2019;152:392-8. [PMID: 31152542 DOI: 10.1093/ajcp/aqz051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
145 Rezk MF, Pieper B. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Adv Ther 2020;37:3732-45. [PMID: 32740789 DOI: 10.1007/s12325-020-01437-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. The Lancet 2022;399:2031-46. [DOI: 10.1016/s0140-6736(22)00466-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Carrillo-Palau M, Hernández-Camba A, Hernández Alvarez-Buylla N, Ramos L, Alonso-Abreu I, Hernández-Pérez A, Vela M, Arranz L, Hernández-Guerra M, González-Gay MÁ, Ferraz-Amaro I. Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:3062. [PMID: 34300227 DOI: 10.3390/jcm10143062] [Reference Citation Analysis]
148 Phisalprapa P, Kositamongkol C, Limsrivilai J, Aniwan S, Charatcharoenwitthaya P, Pisespongsa P, Kitiyakara T, Treepongkaruna S, Chaiyakunapruk N. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. J Med Econ 2020;23:1302-10. [PMID: 32729347 DOI: 10.1080/13696998.2020.1803889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci 2021. [PMID: 34268660 DOI: 10.1007/s10620-021-07129-5] [Reference Citation Analysis]
150 Wang X, Yang YM, Yang T, An LY, Chen XZ, Qi YX, He HY, Fan HB, Sun DL. Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease. J Clin Pharm Ther 2021;46:599-609. [PMID: 33543814 DOI: 10.1111/jcpt.13368] [Reference Citation Analysis]
151 Kochar B, Orkaby AR, Ananthakrishnan AN, Ritchie CS. Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol 2021;14:17562848211025474. [PMID: 34594400 DOI: 10.1177/17562848211025474] [Reference Citation Analysis]
152 Caldera F, Misch EA, Saha S, Wald A, Zhang Y, Hubers J, Megna B, Ley D, Reichelderfer M, Hayney MS. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2019;64:189-95. [PMID: 30317494 DOI: 10.1007/s10620-018-5321-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
153 Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1744-53. [PMID: 33450096 DOI: 10.1111/jgh.15401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Rahme E, Nedjar H, Afif W. Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. J Can Assoc Gastroenterol 2020;3:257-65. [PMID: 33241178 DOI: 10.1093/jcag/gwz025] [Reference Citation Analysis]
155 Bosch S, Wintjens DSJ, Wicaksono A, Pierik M, Covington JA, de Meij TGJ, de Boer NKH. Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. Sensors (Basel) 2022;22:2316. [PMID: 35336485 DOI: 10.3390/s22062316] [Reference Citation Analysis]
156 Bhurwal A, Minacapelli CD, Orosz E, Gupta K, Tait C, Dalal I, Zhang C, Zhao E, Rustgi VK. COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations . World J Gastroenterol 2021; 27(46): 7969-7981 [DOI: 10.3748/wjg.v27.i46.7969] [Reference Citation Analysis]
157 Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review. World J Gastrointest Endosc 2020; 12(12): 542-554 [PMID: 33362907 DOI: 10.4253/wjge.v12.i12.542] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Fang JM, Lamps L, Yeboah-Korang A, Cheng J, Westerhoff M. De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression. Am J Clin Pathol 2021;156:1113-20. [PMID: 34124746 DOI: 10.1093/ajcp/aqab084] [Reference Citation Analysis]
159 Wu S, Zhuang H, Zhao JY, Wang YF. Gastrocolic fistula in Crohn’s disease detected by oral agent contrast-enhanced ultrasound: A case report of a novel ultrasound modality. World J Gastroenterol 2020; 26(17): 2119-2125 [PMID: 32536779 DOI: 10.3748/wjg.v26.i17.2119] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Freeman K, Taylor-Phillips S, Willis BH, Ryan R, Clarke A. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data. BMJ Open 2021;11:e044177. [PMID: 33619196 DOI: 10.1136/bmjopen-2020-044177] [Reference Citation Analysis]
161 Goens D, Micic D. Role of Diet in the Development and Management of Crohn's Disease. Curr Gastroenterol Rep 2020;22:19. [PMID: 32185530 DOI: 10.1007/s11894-020-0755-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Hashash JG, Farraye FA. Health Care Maintenance in Patients with Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.015] [Reference Citation Analysis]
163 Lightner AL, Jia X, Zaghiyan K, Fleshner PR. IPAA in Known Preoperative Crohn's Disease: A Systematic Review. Dis Colon Rectum 2021;64:355-64. [PMID: 33315711 DOI: 10.1097/DCR.0000000000001918] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
164 Lehman HK, Davé R. Candida Glabrata Lymphadenitis Following Infliximab Therapy for Inflammatory Bowel Disease in a Patient With Chronic Granulomatous Disease: Case Report and Literature Review. Front Pediatr 2021;9:707369. [PMID: 34760850 DOI: 10.3389/fped.2021.707369] [Reference Citation Analysis]
165 Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum 2021;64:697-705. [PMID: 33315712 DOI: 10.1097/DCR.0000000000001881] [Reference Citation Analysis]
166 Epistola R, Do T, Vankina R, Wu D, Yeh J, Fleischman MW, Lee JM. Immune Thrombocytopenic Purpura (ITP) as an Uncommon Extraintestinal Complication of Crohn’s Disease: Case Vignette and Systematic Literature Review. Case Reports in Hematology 2020;2020:1-6. [DOI: 10.1155/2020/4785759] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflamm Bowel Dis 2021:izab135. [PMID: 34089259 DOI: 10.1093/ibd/izab135] [Reference Citation Analysis]
168 Malik F, Scherl E, Weber U, Carrino JA, Epsten M, Wichuk S, Pedersen SJ, Paschke J, Schwartzman S, Kroeber G, Maksymowych WP, Longman R, Mandl LA. Utility of magnetic resonance imaging in Crohn's associated sacroiliitis: A cross-sectional study. Int J Rheum Dis 2021;24:582-90. [PMID: 33528900 DOI: 10.1111/1756-185X.14081] [Reference Citation Analysis]
169 Sandall AM, Wall CL, Lomer MC. Nutrition Assessment in Crohn’s Disease using Anthropometric, Biochemical, and Dietary Indexes: A Narrative Review. Journal of the Academy of Nutrition and Dietetics 2020;120:624-40. [DOI: 10.1016/j.jand.2019.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
170 Siegel CA, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. Clinical Gastroenterology and Hepatology 2020;18:1261-7. [DOI: 10.1016/j.cgh.2019.11.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
171 Carlson TJ, Gonzales-Luna AJ, Wilcox MF, Theriault SG, Alnezary FS, Patel P, Ahn BK, Zasowski EJ, Garey KW. Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use. Open Forum Infect Dis 2021;8:ofab419. [PMID: 34646906 DOI: 10.1093/ofid/ofab419] [Reference Citation Analysis]
172 Toma L, Dodot M, Zgura A, Bacalbasa N, Silaghi A, Simu R, Isac T, Mercan-Stanciu A. Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus. Clin Exp Med 2021. [PMID: 34254197 DOI: 10.1007/s10238-021-00743-7] [Reference Citation Analysis]
173 Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy. J Gastrointest Surg 2021;25:211-9. [PMID: 33140318 DOI: 10.1007/s11605-020-04832-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
174 Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions? Nutrients 2021;13:1387. [PMID: 33924119 DOI: 10.3390/nu13041387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
176 Vernia F, Valvano M, Longo S, Cesaro N, Viscido A, Latella G. Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. Nutrients 2022;14:269. [PMID: 35057450 DOI: 10.3390/nu14020269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Ruiz MA, Junior RLK, Quadros LG. Is it time to use hematopoietic stem cell transplantation for severe and refractory crohn's disease? Hematol Transfus Cell Ther. 2020;42:190-191. [PMID: 31601485 DOI: 10.1016/j.htct.2019.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Villanacci V, Reggiani-Bonetti L, Salviato T, Leoncini G, Cadei M, Albarello L, Caputo A, Aquilano MC, Battista S, Parente P. Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica 2021;113:39-53. [PMID: 33686309 DOI: 10.32074/1591-951X-235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Ou G, Enns R. Capsule Endoscopy and Small Bowel Enteroscopy: Have They Rendered the Radiologist Obsolete? Gastrointest Endosc Clin N Am. 2019;29:471-485. [PMID: 31078248 DOI: 10.1016/j.giec.2019.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
181 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Reference Citation Analysis]
182 Chapman BJ, Jones GB. Underscoring the Biochemical Overlap Between Crohn's Disease and Depression. Am J Gastroenterol 2019;114:827-8. [PMID: 30676365 DOI: 10.14309/ajg.0000000000000063] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Bruining DH, Oliva S, Fleisher MR, Fischer M, Fletcher JG; BLINK study group. Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn's disease: a multicentre, prospective study.BMJ Open Gastroenterol. 2020;7. [PMID: 32499275 DOI: 10.1136/bmjgast-2019-000365] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
184 MacFarlane H, Baldock TE, McLean RC, Brown LR. Patient Outcomes Following Emergency Bowel Resection for Inflammatory Bowel Disease and the Impact of Surgical Subspecialisation in the North of England: A Retrospective Cohort Study. World J Surg 2021;45:1376-89. [PMID: 33506292 DOI: 10.1007/s00268-020-05947-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn's disease. Curr Opin Gastroenterol 2021;37:351-6. [PMID: 33731644 DOI: 10.1097/MOG.0000000000000735] [Reference Citation Analysis]
186 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
187 Tse SS, Sands BE, Keefer L, Cohen BL, Maser E, Ungaro RC, Marion JF, Colombel JF, Itzkowitz SH, Gelman J, Dubinsky MC. Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home. J Pharm Pract 2021;:8971900211000682. [PMID: 33827316 DOI: 10.1177/08971900211000682] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Dąbkowski K, Graca-pakulska K, Zawada I, Ostrowski J, Starzyńska T. Clinical significance of endoscopic findings in the upper gastrointestinal tract in Crohn’s disease. Scandinavian Journal of Gastroenterology 2019;54:1075-80. [DOI: 10.1080/00365521.2019.1656776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
189 Sands BE, Irving PM, Hoops T, Izanec JL, Gao L, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, Afzali A, Aitova L, Aldeguer i Mante X, Allez M, Altorjay I, Argüelles Arias F, Armuzzi A, Augustyn M, Bafutto M, Barrio J, Begun J, Behrend C, Bezemer G, Bonnaud G, Brankovic M, Byung IJ, Calvet Calvo X, Chachu K, Chebli JMF, Cheon JH, Cichoz-lach H, Clark L, Cummings F, Dalal K, Danese S, De Boer N, De Lourdes Ferrari M, Désilets E, Dugalic P, Duvall G, Fedorishina O, Filip R, Flores C, Fogel R, Fon J, Frankel M, Friedenberg K, Fries W, Galina V, Gietka P, Goel R, Hasselblatt P, Herfarth H, Herszényi L, Hindryckx P, Hoentjen F, Horjus Talabur Horje C, Iduru S, Irving P, Isfort R, Jairath V, Jones M, Kalimullina D, Katz J, Kaur M, Khurana SK, Kim JS, Kim Y, Kleczkowski D, Knezevic S, Knoll A, Korman LY, Kotzev I, Kulyapin A, Lee KM, Leemreis D, Leszczyszyn J, Limdi J, Lissauer J, Loftus E, Malecka-panas E, Marshall J, Mihály E, Milan L, Monteleone G, Nagorni A, Owczarek D, Palekar N, Panaccione R, Park YS, Park SH, Parra R, Patai Á, Patel K, Patel B, Pershko A, Petrova E, Pineton de Chambrun G, Randall C, Riestra Menendez S, Ritter T, Rivero M, Roblin X, Rocca R, Romatowski J, Rydzewska G, Saibeni S, Salzberg B, Sarles H, Saunders J, Savarino EV, Serclova Z, Shchukina O, Siegel J, Soofi N, Sparrow M, Stokesberry D, Suiter D, Svorcan P, Tkachev A, Tsonev N, Tünde K, Ulbrych J, Vanasek T, Varga M, Vermeire S, Vicente Lidon R, Weiss ML, Wesley E, Winstead N, Wojcik K, Wypych J, Zaltman C, Zdena Z. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet 2022;399:2200-11. [DOI: 10.1016/s0140-6736(22)00688-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kelm M, Anger F, Eichlinger R, Brand M, Kim M, Reibetanz J, Krajinovic K, Germer CT, Schlegel N, Flemming S. Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease. J Clin Med 2021;10:731. [PMID: 33673222 DOI: 10.3390/jcm10040731] [Reference Citation Analysis]
191 Mago S, Vaziri H, Tadros M. The Usefulness of Fecal Calprotectin in the era of the COVID-19 Pandemic. Gastroenterology 2021;160:2623-5. [PMID: 32425230 DOI: 10.1053/j.gastro.2020.05.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
192 Gonçalves BP, Flauzino T, Inoue CJ, de Paula JCC, Galvão TC, de Alcantara CC, Miyazaki PK, Rosa L, Westmore S, Lozovoy MAB, Reiche EMV, Simão ANC. IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease. Int J Colorectal Dis 2021;36:383-93. [PMID: 33047210 DOI: 10.1007/s00384-020-03743-3] [Reference Citation Analysis]
193 El Ouali S, Click B, Holubar SD, Rieder F. Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. United European Gastroenterol J 2020;8:263-70. [PMID: 32213020 DOI: 10.1177/2050640620901960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
194 Oliveira MC, Elias JB, Moraes DA, Simões BP, Rodrigues M, Ribeiro AAF, Piron-Ruiz L, Ruiz MA, Hamerschlak N. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther 2021;43:65-86. [PMID: 32418777 DOI: 10.1016/j.htct.2020.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
195 Snyder EF, Davis S, Aldrich K, Veerabagu M, Larussa T, Abenavoli L, Boccuto L. Crohn disease: Identification, diagnosis, and clinical management. Nurse Pract 2021;46:22-30. [PMID: 34808643 DOI: 10.1097/01.NPR.0000798212.61425.4f] [Reference Citation Analysis]
196 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
197 Tu T, Yu M, Zhang Y, Shi X, Xu J, Hu J, Gan J, He W, Dong L, Han J, Huang Z, Pan Y, Zhang J. A novel fluorinated triazole derivative suppresses macrophage activation and alleviates experimental colitis via a Twist1-dependent pathway. Biochemical Pharmacology 2018;155:275-87. [DOI: 10.1016/j.bcp.2018.07.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
198 McNeill MB, Suarez Y, Axelrad J. Obliterative Muscularization of the Small Bowel Submucosa in Fibrostenotic Crohn's Disease. ACG Case Rep J 2020;7:e00357. [PMID: 32548188 DOI: 10.14309/crj.0000000000000357] [Reference Citation Analysis]
199 Havlichek D, Guerrero Vinsard D, Pignolo RJ, Kane S. Crohn's Disease in a Patient With Fibrodysplasia Ossificans Progressiva. ACG Case Rep J 2022;9:e00737. [DOI: 10.14309/crj.0000000000000737] [Reference Citation Analysis]
200 Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020;34:395-404. [PMID: 32103457 DOI: 10.1007/s40259-020-00409-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
201 Lenahan KL, Nichols DE, Gertler RM, Chambers JD. Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans. Health Aff (Millwood) 2021;40:1749-57. [PMID: 34724434 DOI: 10.1377/hlthaff.2021.00822] [Reference Citation Analysis]
202 Sun Y, Geng J, Chen X, Chen H, Wang X, Chen J, Li X, Hesketh T. Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study. Inflamm Bowel Dis 2021:izab300. [PMID: 34849925 DOI: 10.1093/ibd/izab300] [Reference Citation Analysis]
203 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Reference Citation Analysis]
204 Linson EA, Hanauer SB. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep 2021;23:16. [PMID: 34338892 DOI: 10.1007/s11894-021-00816-3] [Reference Citation Analysis]
205 Li H, Xie L, Yao H, Zhang L, Liang S, Lyu W. Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn’s Disease. IMCRJ 2022;Volume 15:117-24. [DOI: 10.2147/imcrj.s346159] [Reference Citation Analysis]
206 Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, Horst SN, Schwartz DA, Adams DW, Freiberg MS, Gatskie V, King S, Abney LR, Beaulieu DB. Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. PLoS One 2020;15:e0230656. [PMID: 32214373 DOI: 10.1371/journal.pone.0230656] [Reference Citation Analysis]
207 Smith R, Hubers J, Farraye FA, Sampene E, Hayney MS, Caldera F. Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:2935-41. [PMID: 32995995 DOI: 10.1007/s10620-020-06631-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
208 Feld L, Glick LR, Cifu AS. Diagnosis and Management of Crohn Disease. JAMA 2019;321:1822-3. [PMID: 30969326 DOI: 10.1001/jama.2019.3684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
209 Gao Z, Wang P, Hong J, Yan Y, Tong T, Wu B, Hu J, Wang Z. Health-related quality of life among Chinese patients with Crohn's disease: a cross-sectional survey using the EQ-5D-5L. Health Qual Life Outcomes 2022;20:62. [PMID: 35413910 DOI: 10.1186/s12955-022-01969-z] [Reference Citation Analysis]
210 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
211 Wynne B, Mchugh L, Gao W, Keegan D, Byrne K, Rowan C, Hartery K, Kirschbaum C, Doherty G, Cullen G, Dooley B, Mulcahy HE. Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. Gastroenterology 2019;156:935-945.e1. [DOI: 10.1053/j.gastro.2018.11.030] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 13.7] [Reference Citation Analysis]
212 Nag A, Romero B. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease. Health Qual Life Outcomes 2022;20:75. [PMID: 35525935 DOI: 10.1186/s12955-022-01975-1] [Reference Citation Analysis]
213 Bajaj J, Brenner D, Cai Q, Cash B, Crowell M, Dibaise J, Gallegos-orozco J, Gardner T, Gyawali C, Ha C, Holtmann G, Jamil L, Kaplan G, Karsan H, Kinoshita Y, Lebwohl B, Leontiadis G, Lichtenstein G, Longstreth G, Muthusamy V, Oxentenko A, Pimentel M, Pisegna J, Rubenstein J, Russo M, Saini S, Samadder N, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Juez Sáez LD, Ocaña J, Ramos D, Die J, García Pérez JC. Management of anastomotic stenosis after ileocecal resection in Crohn's disease with stenotic pattern surgery vs. endoscopic dilation. Surgery vs. endoscopic dilation. Cir Esp (Engl Ed) 2020:S0009-739X(20)30267-0. [PMID: 32919700 DOI: 10.1016/j.ciresp.2020.08.001] [Reference Citation Analysis]
215 Rogler G, Scharl M, Spalinger M, Yilmaz B, Zaugg M, Hersberger M, Schreiner P, Biedermann L, Herfarth H. Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies? Mol Nutr Food Res 2021;65:e2000514. [PMID: 33433954 DOI: 10.1002/mnfr.202000514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Sun W, Lirio RA, Schneider J, Aubrecht J, Kadali H, Baratta M, Gulati P, Suri A, Lin T, Vasudevan R, Rosario M. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. Clin Pharmacol Drug Dev 2021;10:734-47. [PMID: 33331142 DOI: 10.1002/cpdd.891] [Reference Citation Analysis]
217 Larmie J, Vasilyeva D, Yunov G, Peters SM. Vestibular ulceration in a 20-year-old woman. J Am Dent Assoc 2021:S0002-8177(21)00137-9. [PMID: 34049677 DOI: 10.1016/j.adaj.2021.03.002] [Reference Citation Analysis]
218 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Reference Citation Analysis]
219 Salem G, Ding K, Sakuraba A, Cohen R. Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review. J Investig Med 2021:jim-2020-001699. [PMID: 33622709 DOI: 10.1136/jim-2020-001699] [Reference Citation Analysis]
220 Palacios Argueta P, Salazar M, Attar B, Simons-Linares R, Shen B. 90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors. Inflamm Bowel Dis 2021;27:530-7. [PMID: 32812037 DOI: 10.1093/ibd/izaa224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Mehta K, Kurtz MT. Upper Gastrointestinal Manifestations of Crohn's Disease: Differential Diagnosis and Treatment of an Uncommon Presentation of Crohn's Disease. Mil Med 2021:usab517. [PMID: 34893877 DOI: 10.1093/milmed/usab517] [Reference Citation Analysis]
222 Yin AL, Hachuel D, Pollak JP, Scherl EJ, Estrin D. Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. J Med Internet Res. 2019;21:e14630. [PMID: 31429410 DOI: 10.2196/14630] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
223 Sung KY, Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Hou MC, Lu CL, Wang YP, Chen MH. Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. Aliment Pharmacol Ther 2022;55:1192-201. [PMID: 35261051 DOI: 10.1111/apt.16856] [Reference Citation Analysis]
224 Mazzurana L, Bonfiglio F, Forkel M, D'Amato M, Halfvarson J, Mjösberg J. Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells. Inflamm Bowel Dis 2021;27:1128-38. [PMID: 33295628 DOI: 10.1093/ibd/izaa316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Afecto EMP, Rodrigues MAR, Ponte AIL, Fernandes SS. Thinking outside the box of ascites differential diagnosis. Eur J Gastroenterol Hepatol 2021;33:940-1. [PMID: 33908389 DOI: 10.1097/MEG.0000000000001828] [Reference Citation Analysis]
226 Schulberg JD, Wright EK, Holt BA, Wilding HE, Hamilton AL, Ross AL, Kamm MA. Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. J Gastroenterol Hepatol 2021;36:344-61. [PMID: 33150989 DOI: 10.1111/jgh.15330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Chen BX, Han ZM, Zhou Q, Liu HB, Xu PC, Zhi FC. Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn's disease. Scand J Gastroenterol 2021;56:812-9. [PMID: 33962533 DOI: 10.1080/00365521.2021.1922748] [Reference Citation Analysis]
228 O'Brien KJ, Parisi X, Shelman NR, Merideth MA, Introne WJ, Heller T, Gahl WA, Malicdan MCV, Gochuico BR. Inflammatory bowel disease in Hermansky-Pudlak syndrome: a retrospective single-centre cohort study. J Intern Med 2021;290:129-40. [PMID: 33423334 DOI: 10.1111/joim.13224] [Reference Citation Analysis]
229 Aardoom MA, Klomberg RCW, Kemos P, Ruemmele FM, van Ommen H, de Ridder L, Croft NM. The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease; a prospective international cohort study based on the PIBD-SETQuality Safety Registry. J Crohns Colitis 2021:jjab171. [PMID: 34599822 DOI: 10.1093/ecco-jcc/jjab171] [Reference Citation Analysis]
230 Radford SJ, Clarke C, Shinkins B, Leighton P, Taylor S, Moran G. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101897] [Reference Citation Analysis]
231 Harrison N, Humes R, Singla M. Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:1819-21. [PMID: 34279011 DOI: 10.14309/ajg.0000000000001380] [Reference Citation Analysis]
232 de Campos RJDS, Lucchetti G, Lucchetti ALG, Chebli LA, Schettino Pereira L, Chebli JMF. Influence of Religiousness and Spirituality on Remission Rate, Mental Health, and Quality of Life of Patients With Active Crohn's Disease: A Longitudinal 2-Year Follow-up Study. J Crohns Colitis 2021;15:55-63. [PMID: 32582934 DOI: 10.1093/ecco-jcc/jjaa130] [Reference Citation Analysis]
233 El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O. Stem cell transplantation for induction of remission in medically refractory Crohn's disease. Cochrane Database Syst Rev 2022;5:CD013070. [PMID: 35556242 DOI: 10.1002/14651858.CD013070.pub2] [Reference Citation Analysis]
234 Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, Sandler RS. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-TNF Agents in Older Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00927-7. [PMID: 34481954 DOI: 10.1016/j.cgh.2021.08.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
235 Chao K, Huang Y, Zhu X, Tang J, Wang X, Lin L, Guo H, Zhang C, Li M, Yang Q, Huang J, Ye L, Hu P, Huang M, Cao Q, Gao X. Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther 2021;54:1124-33. [PMID: 34563096 DOI: 10.1111/apt.16600] [Reference Citation Analysis]
236 Manka P, Sydor S, Wase N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, von Arnim U, Coombes JD, Cubero FJ, Kahraman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G, Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. Liver Int 2021. [PMID: 34219348 DOI: 10.1111/liv.15003] [Reference Citation Analysis]
237 Yu N, Sarwal D, Ash R, Aslinia FM. Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual. BMJ Case Rep 2021;14:e243500. [PMID: 34645625 DOI: 10.1136/bcr-2021-243500] [Reference Citation Analysis]
238 Siegel CA, Yang F, Eslava S, Cai Z. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. Clin Transl Gastroenterol 2020;11:e00128. [PMID: 32463619 DOI: 10.14309/ctg.0000000000000128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
239 Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis 2020;14:1354-63. [PMID: 32648579 DOI: 10.1093/ecco-jcc/jjaa050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
240 Hu AB, Burke KE, Kochar B, Ananthakrishnan AN. Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. Inflamm Bowel Dis 2021;27:779-86. [PMID: 32812048 DOI: 10.1093/ibd/izaa205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
241 Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y, Sharpe AR, Reichelderfer M, Hayney MS. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflamm Bowel Dis. 2020;26:593-602. [PMID: 31504526 DOI: 10.1093/ibd/izz164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
242 Freeman K, Ryan R, Parsons N, Taylor-Phillips S, Willis BH, Clarke A. Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database. Br J Gen Pract 2021;71:e854-61. [PMID: 34607795 DOI: 10.3399/BJGP.2021.0125] [Reference Citation Analysis]
243 Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis 2021;27:1201-9. [PMID: 33107564 DOI: 10.1093/ibd/izaa270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Fujimura T, Yamada Y, Umeyama T, Kudo Y, Kanamori H, Mori T, Shimizu T, Kato M, Kawaida M, Hosoe N, Hasegawa Y, Matsubara K, Shimojima N, Shinoda M, Obara H, Naganuma M, Kitagawa Y, Hoshino K, Kuroda T. Maintenance treatment with infliximab for ulcerative ileitis after intestinal transplantation: A case report. World J Clin Cases 2021; 9(19): 5270-5279 [PMID: 34307578 DOI: 10.12998/wjcc.v9.i19.5270] [Reference Citation Analysis]
245 Su J, Ren Y, Liu L, Hu Y, Shi H, Ren J, Xie C. Decreased serum iron concentration and total iron binding capacity are associated with serious Crohn's disease. Sci Rep 2022;12:3923. [PMID: 35273280 DOI: 10.1038/s41598-022-07948-0] [Reference Citation Analysis]
246 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
247 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
248 Le Berre C, Trang-Poisson C, Bourreille A. Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review. World J Gastroenterol 2019; 25(31): 4534-4554 [PMID: 31496630 DOI: 10.3748/wjg.v25.i31.4534] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
249 Wallace ZS, Sparks JA. Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. JAMA 2021;326:2370-2. [PMID: 34932096 DOI: 10.1001/jama.2021.21315] [Reference Citation Analysis]
250 Palchaudhuri S, Albenberg L, Lewis JD. Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. Crohns Colitis 360 2020;2:otaa059. [PMID: 33954288 DOI: 10.1093/crocol/otaa059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
251 Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-sánchez JN. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology 2019;17:1788-1798.e2. [DOI: 10.1016/j.cgh.2018.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
252 Choe MY, Wright R, Parian A. Follow-up Care in Inflammatory Bowel Disease: An Integrative Review. Gastroenterol Nurs 2021;44:E48-R58. [PMID: 34037572 DOI: 10.1097/SGA.0000000000000570] [Reference Citation Analysis]
253 Gomes TNF, de Azevedo FS, Argollo M, Miszputen SJ, Ambrogini O Jr. Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil. Clin Exp Gastroenterol 2021;14:91-102. [PMID: 33762838 DOI: 10.2147/CEG.S288688] [Reference Citation Analysis]
254 Reinisch W, Mishkin DS, Oh YS, Schreiber S, Hussain F, Jacob R, Hassanali A, Daperno M. Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. Gastrointest Endosc 2021;93:174-182.e2. [PMID: 32464142 DOI: 10.1016/j.gie.2020.05.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
255 Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther 2020;51:1031-8. [PMID: 32329532 DOI: 10.1111/apt.15719] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
256 Johnson LM, White SK, Schmidt RL. Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease? Clin Chim Acta 2020;510:191-5. [PMID: 32673669 DOI: 10.1016/j.cca.2020.07.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Rubin DT, Sninsky C, Siegmund B, Sans M, Hart A, Bressler B, Bouhnik Y, Armuzzi A, Afzali A. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis 2021:izab006. [PMID: 33512475 DOI: 10.1093/ibd/izab006] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
258 Shah R, Elangovan A, Jordan DW, Katz J, Cooper GS. 10-Year Trend of Abdominal Magnetic Resonance Imaging Compared With Abdominal Computed Tomography Scans in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab284. [PMID: 34935946 DOI: 10.1093/ibd/izab284] [Reference Citation Analysis]
259 Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc., Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open 2021;4:e2129639. [PMID: 34661663 DOI: 10.1001/jamanetworkopen.2021.29639] [Reference Citation Analysis]
260 Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00252-1. [PMID: 34388360 DOI: 10.1016/S2468-1253(21)00252-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol 2019;10:212. [PMID: 30930775 DOI: 10.3389/fphar.2019.00212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
262 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
263 Tamura S, Ishida N, Miyazu T, Onoue S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. Sci Rep 2020;10:21353. [PMID: 33288852 DOI: 10.1038/s41598-020-78603-9] [Reference Citation Analysis]
264 East JE, Boyapati RK, Torres J, Parker CE, MacDonald JK, Chande N, Feagan BG. Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. Inflamm Bowel Dis 2019;25:472-8. [PMID: 30789982 DOI: 10.1093/ibd/izy268] [Reference Citation Analysis]
265 Zhu P, Sun JF, Gu YF, Chen HJ, Xu MM, Li YR, Yang BL. Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study. BMC Gastroenterol 2022;22:15. [PMID: 35012467 DOI: 10.1186/s12876-021-02078-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:563-577. [PMID: 31023087 DOI: 10.1080/17474124.2019.1608818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
267 Cohen-Mekelburg S, Waljee AK. Inflammatory Bowel Disease in the Older Adult. Clin Geriatr Med 2021;37:185-95. [PMID: 33213772 DOI: 10.1016/j.cger.2020.08.013] [Reference Citation Analysis]
268 Papalia I, Tjandra D, Quah S, Tan C, Gorelik A, Sivanesan S, Macrae F. Colon Capsule Endoscopy in the Assessment of Mucosal Healing in Crohn's Disease. Inflamm Bowel Dis 2021;27:S25-32. [PMID: 34791289 DOI: 10.1093/ibd/izab180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Hashash JG, Picco MF, Farraye FA. Health Maintenance for Adult Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2021;19:583-96. [PMID: 34840495 DOI: 10.1007/s11938-021-00364-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Hernández-Camba A, Carrillo-Palau M, Ramos L, Hernández Alvarez-Buylla N, Alonso-Abreu I, Hernández-Pérez A, Vela M, Arranz L, Hernández-Guerra M, González-Gay MÁ, Ferraz-Amaro I. Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. J Clin Med 2021;10:1671. [PMID: 33924727 DOI: 10.3390/jcm10081671] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Feuerstein JD, Rakowsky S, Sattler L, Yadav A, Foromera J, Grossberg L, Cheifetz AS. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019;pii:S0016-5107(19)31602-5. [PMID: 31009609 DOI: 10.1016/j.gie.2019.04.219] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
272 Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, Yi Y, Singer J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:104-10. [DOI: 10.1016/j.cgh.2020.02.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
273 Linssen MD, Hooghiemstra WTR, Jorritsma-Smit A, Allersma DP, Dijkstra G, Nagengast WB. Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:922. [PMID: 34577622 DOI: 10.3390/ph14090922] [Reference Citation Analysis]
274 Hart A, D'Haens G, Bereswill M, Finney-Hayward T, Kalabic J, Levy G, Liang H, Seow CH, Loftus EV Jr, Panaccione R, Reinisch W, Satsangi J. Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. United European Gastroenterol J 2022. [PMID: 35560533 DOI: 10.1002/ueg2.12236] [Reference Citation Analysis]
275 Claytor JD, Viramontes O, Conner S, Wen KW, Beck K, Chin-Hong PV, Henrich TJ, Peluso MJ. TNF-α inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines. AIDS 2021;35:2163-8. [PMID: 34115645 DOI: 10.1097/QAD.0000000000002985] [Reference Citation Analysis]
276 Chen B, Gao X, Zhong J, Ren J, Zhu X, Liu Z, Wu K, Kalabic J, Yu Z, Huang B, Kwatra N, Doan T, Robinson AM, Chen MH. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. Therap Adv Gastroenterol 2020;13:1756284820938960. [PMID: 32733600 DOI: 10.1177/1756284820938960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
277 Narula N, Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF, Reinisch W. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00394-3. [PMID: 33838348 DOI: 10.1016/j.cgh.2021.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Sharma A, Phulia A, Sethi RS. PET/computed tomography enterography. Nucl Med Commun 2021;42:694-8. [PMID: 33560721 DOI: 10.1097/MNM.0000000000001373] [Reference Citation Analysis]
279 Du W, Han W, Dong J. Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis. Med Hypotheses 2020;144:110211. [PMID: 33254520 DOI: 10.1016/j.mehy.2020.110211] [Reference Citation Analysis]
280 Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2021:jjab133. [PMID: 34402887 DOI: 10.1093/ecco-jcc/jjab133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Gustavo Kotze P, Peyrin-Biroulet L, Magro F. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00315-7. [PMID: 34187768 DOI: 10.1016/j.dld.2021.05.038] [Reference Citation Analysis]
282 Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
283 Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev 2021;1:CD013529. [PMID: 33471939 DOI: 10.1002/14651858.CD013529.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
284 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
285 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
286 Wyness SP, Lin L, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. J Appl Lab Med 2021;6:931-41. [PMID: 33582792 DOI: 10.1093/jalm/jfaa236] [Reference Citation Analysis]
287 Fletcher J, Cooper SC, Ghosh S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients. 2019;11. [PMID: 31067701 DOI: 10.3390/nu11051019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
288 Sienkiewicz M, Szymańska P, Maciejewska O, Niewiadomska J, Wiśniewska‐jarosińska M, Fichna J. Assessment of dietary habits in inflammatory bowel disease patients: A cross‐sectional study from Poland. Nutr Bull 2021;46:432-42. [DOI: 10.1111/nbu.12525] [Reference Citation Analysis]
289 Sun XL, Qiao LC, Gong J, Wen K, Xu ZZ, Yang BL. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn’s disease. World J Gastroenterol 2021; 27(35): 5946-5957 [PMID: 34629811 DOI: 10.3748/wjg.v27.i35.5946] [Reference Citation Analysis]
290 Falloon KA, Fiocchi C. Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change? EMJ Innov. [DOI: 10.33590/emjinnov/21-00134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel Dis 2021;27:1674-83. [PMID: 33295611 DOI: 10.1093/ibd/izaa318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.Biomolecules. 2021;11. [PMID: 33440772 DOI: 10.3390/biom11010082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
293 De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, Santarcangelo C, Tantipongpiradet A, Daglia M. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. Int J Mol Sci 2020;21:E4929. [PMID: 32668581 DOI: 10.3390/ijms21144929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
294 Zhao S, Xie Q, Zhao Z. Reply to Comment on "Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis" by Li Y and Liu X. Inflamm Bowel Dis 2019;25:e78-81. [PMID: 30851039 DOI: 10.1093/ibd/izz028] [Reference Citation Analysis]
295 Tran V, Limketkai BN, Sauk JS. IBD in the Elderly: Management Challenges and Therapeutic Considerations. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0720-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
296 Liu M, Li D, Hong X, Sun Z. Increased Risk for Dementia in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. Front Neurol 2022;13:813266. [DOI: 10.3389/fneur.2022.813266] [Reference Citation Analysis]
297 Jiang M, Zeng Z, Chen K, Dang Y, Li L, Ma C, Cheng R, Hu K, Li X, Zhang H. Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis. Front Immunol 2022;13:820891. [PMID: 35371004 DOI: 10.3389/fimmu.2022.820891] [Reference Citation Analysis]
298 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
299 Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology 2020;158:2123-2138.e8. [PMID: 32044319 DOI: 10.1053/j.gastro.2020.01.047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 20.0] [Reference Citation Analysis]
300 Kamal A, Padival R, Lashner B. Inflammatory Bowel Disease and Irritable Bowel Syndrome: What to Do When There Is an Overlap. Inflamm Bowel Dis 2018;24:2479-82. [PMID: 30169572 DOI: 10.1093/ibd/izy277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
301 Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open. 2019;9:e027428. [PMID: 30852550 DOI: 10.1136/bmjopen-2018-027428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
302 Azzman N. Crohn's Disease: Potential Drugs for Modulation of Autophagy. Medicina (Kaunas) 2019;55:E224. [PMID: 31146413 DOI: 10.3390/medicina55060224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
303 Lucafò M, Franca R, Selvestrel D, Curci D, Pugnetti L, Decorti G, Stocco G. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2018;14:1209-23. [PMID: 30465611 DOI: 10.1080/17425255.2018.1551876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
304 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
305 Abushamma S, Ballard DH, Smith RK, Deepak P. Multidisciplinary management of perianal Crohn's disease. Curr Opin Gastroenterol 2021;37:295-305. [PMID: 33899777 DOI: 10.1097/MOG.0000000000000751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Grażyńska A, Kufel J, Dudek A, Cebula M. Shear Wave and Strain Elastography in Crohn's Disease-A Systematic Review. Diagnostics (Basel) 2021;11:1609. [PMID: 34573952 DOI: 10.3390/diagnostics11091609] [Reference Citation Analysis]
307 Agrawal G, Clancy A, Sharma R, Huynh R, Ramrakha S, Borody T. Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series. Microorganisms 2020;8:E371. [PMID: 32155771 DOI: 10.3390/microorganisms8030371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
308 Dehghan M, Wong G, Neuberger E, Kin C, Rieder F, Park KT. Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA. BMJ Open Gastroenterol 2021;8:e000781. [PMID: 34930755 DOI: 10.1136/bmjgast-2021-000781] [Reference Citation Analysis]
309 Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020;18:1346-1355. [PMID: 31927105 DOI: 10.1016/j.cgh.2019.12.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
310 Herndon K, Dewitt A, Gillion A, Pattanaik D. Infusion-related angioedema associated with infliximab-abda: Case report. American Journal of Health-System Pharmacy 2021;78:108-12. [DOI: 10.1093/ajhp/zxaa321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-hussuna A, Ellul P, Frei-lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Kenneth Marshall J, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 2020;14:4-22. [DOI: 10.1093/ecco-jcc/jjz180] [Cited by in Crossref: 184] [Cited by in F6Publishing: 153] [Article Influence: 61.3] [Reference Citation Analysis]
312 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
313 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
314 Burr NE, Hall B, Hamlin PJ, Selinger CP, Ford AC, O'Connor A. Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. J Crohns Colitis 2019;13:693-701. [PMID: 30561586 DOI: 10.1093/ecco-jcc/jjy216] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
315 Gonen C, Surmelioglu A, Kochan K, Ozer S, Aslan E, Tilki M. Impact of intestinal ultrasound with a portable system in the management of Crohn's disease. Gastroenterol Rep (Oxf) 2021;9:418-26. [PMID: 34733527 DOI: 10.1093/gastro/goaa088] [Reference Citation Analysis]
316 Shafiee NH, Manaf ZA, Mokhtar NM, Raja Ali RA. Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? Intest Res 2021;19:171-85. [PMID: 33525858 DOI: 10.5217/ir.2020.00035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
317 Carvello M, Danese S, Spinelli A. Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. Clin Colon Rectal Surg 2022;35:072-7. [DOI: 10.1055/s-0041-1740031] [Reference Citation Analysis]
318 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
319 Majidova K, Handfield J, Kafi K, Martin RD, Kubinski R. Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review. Genes (Basel) 2021;12:1465. [PMID: 34680860 DOI: 10.3390/genes12101465] [Reference Citation Analysis]
320 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
321 Kochar B, Cai W, Cagan A, Ananthakrishnan AN. Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2020;158:2104-2111.e2. [PMID: 32105728 DOI: 10.1053/j.gastro.2020.02.032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
322 Kumar P, Vuyyuru SK, Kante B, Sahu P, Goyal S, Madhu D, Jain S, Ranjan MK, Mundhra S, Golla R, Singh M, Virmani S, Gupta A, Yadav N, Kalaivani M, Sharma R, Das P, Makharia G, Kedia S, Ahuja V. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther 2022;55:1431-40. [PMID: 35229906 DOI: 10.1111/apt.16839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
323 Hasbey I, Ufuk F, Kaya F, Celik M. Cardiac MRI findings in patients with Crohn's disease. Ir J Med Sci 2021. [PMID: 34279800 DOI: 10.1007/s11845-021-02717-w] [Reference Citation Analysis]
324 Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71:1599-1613. [PMID: 31436036 DOI: 10.1002/art.41042] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 41.3] [Reference Citation Analysis]
325 Choe MY, VanGraafeiland B, Parian A. Improving Follow-ups With Gastroenterologists Utilizing an Appointment Scheduling Protocol in Inflammatory Bowel Disease: A Quality Improvement Project. Gastroenterol Nurs 2021;44:E91-E100. [PMID: 34411015 DOI: 10.1097/SGA.0000000000000635] [Reference Citation Analysis]
326 Choi YI, Kim YJ, Chung JW, Kim KO, Kim H, Park RW, Park DK. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform 2020;8:e15124. [PMID: 32293578 DOI: 10.2196/15124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
327 Vuitton L, Peyrin-biroulet L. Pharmacological Prevention of Postoperative Recurrence in Crohn’s Disease. Drugs 2020;80:385-99. [DOI: 10.1007/s40265-020-01266-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
328 Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, Leibovitzh H, Banai Eran H, Aharoni Golan M, Rabinowitz K, Ziv Baran T, Lavie I, Yadgar K, Zonensain K, Kopylov U, Ben Horin S, Eliakim R, Waterman M, Chowers Y, Ben-Shachar S, Dotan I; Israeli IBD Research Nucleus. Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clin Gastroenterol Hepatol 2021;19:1564-1572.e5. [PMID: 32629126 DOI: 10.1016/j.cgh.2020.06.069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Gordon M, Grafton-clarke C, Akobeng A, Macdonald J, Chande N, Hanauer S, Arnott I. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review. Frontline Gastroenterol 2021;12:423-36. [DOI: 10.1136/flgastro-2020-101405] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
330 Kelm M, Germer CT, Schlegel N, Flemming S. The Revival of Surgery in Crohn's Disease-Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021;9:1317. [PMID: 34680434 DOI: 10.3390/biomedicines9101317] [Reference Citation Analysis]
331 Friedberg S, Rubin DT. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am 2022;51:369-79. [PMID: 35595420 DOI: 10.1016/j.gtc.2021.12.011] [Reference Citation Analysis]
332 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
333 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
334 Kataria R, Pickett-blakely O. The Mediterranean Diet in Gastrointestinal and Liver Diseases. Curr Treat Options Gastro 2020;18:718-28. [DOI: 10.1007/s11938-020-00318-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Zhou C, Li M, Zhang Y, Ni M, Wang Y, Xu D, Shi Y, Zhang B, Chen Y, Huang Y, Zhang S, Shi H, Jiang B. Autologous adipose-derived stem cells for the treatment of Crohn's fistula-in-ano: an open-label, controlled trial. Stem Cell Res Ther 2020;11:124. [PMID: 32183875 DOI: 10.1186/s13287-020-01636-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
336 Yamamoto T, Lightner AL, Spinelli A, Kotze PG. Perioperative management of ileocecal Crohn's disease in the current era. Expert Rev Gastroenterol Hepatol 2020;14:843-55. [PMID: 32729736 DOI: 10.1080/17474124.2020.1802245] [Reference Citation Analysis]
337 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 148.0] [Reference Citation Analysis]
338 Swier RM, Siebrasse A, Coscia E, Peery AF. Diet in Benign Colonic Disorders: A Narrative Review. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.010] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
339 Yu B, Zhao L, Jin S, He H, Zhang J, Wang X. Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease. Front Immunol 2022;13:828219. [DOI: 10.3389/fimmu.2022.828219] [Reference Citation Analysis]
340 Broder JS, Oliveira J E Silva L, Bellolio F, Freiermuth CE, Griffey RT, Hooker E, Jang TB, Meltzer AC, Mills AM, Pepper JD, Prakken SD, Repplinger MD, Upadhye S, Carpenter CR. Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE-2): Low-risk, recurrent abdominal pain in the emergency department. Acad Emerg Med 2022;29:526-60. [PMID: 35543712 DOI: 10.1111/acem.14495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Frias Gomes C, Chapman TP, Satsangi J. De-escalation of medical therapy in inflammatory bowel disease. Curr Opin Pharmacol 2020;55:73-81. [PMID: 33160250 DOI: 10.1016/j.coph.2020.09.014] [Reference Citation Analysis]
342 Grosen A, Bellaguarda E, Nersting J, Hvas CL, Liljeqvist-Soltic I, Stein A, Christensen LA, Ruderman EM, Brown CR, Schmiegelow K, Zhang JX, Kelsen J, Hanauer SB. Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflamm Bowel Dis 2021:izab205. [PMID: 34463329 DOI: 10.1093/ibd/izab205] [Reference Citation Analysis]
343 Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 2020;145:757-65. [PMID: 31866436 DOI: 10.1016/j.jaci.2019.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
344 Aoun R, Jabak S, Mourad FH, Francis FF, Regueiro M, Hashash JG. First or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy? J Clin Gastroenterol 2021;55:740-6. [PMID: 34294654 DOI: 10.1097/MCG.0000000000001591] [Reference Citation Analysis]
345 Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
346 Kline BP, Weaver T, Brinton DL Jr, Harris L, Yochum GS, Berg AS, Koltun WA. Clinical and Genetic Factors Impact Time to Surgical Recurrence After Ileocolectomy for Crohn's Disease. Ann Surg 2021;274:346-51. [PMID: 31714311 DOI: 10.1097/SLA.0000000000003660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Dotimas J, Das M, Martin D. Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review. SAGE Open Med Case Rep 2020;8:2050313X20937223. [PMID: 32655868 DOI: 10.1177/2050313X20937223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol 2020;3:234-42. [PMID: 32905124 DOI: 10.1093/jcag/gwz044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
349 Juez Sáez LD, Ocaña J, Ramos D, Die J, García Pérez JC. Management of anastomotic stenosis after ileocecal resection in Crohn's disease with stenotic pattern surgery vs. endoscopic dilation. Surgery vs. endoscopic dilation. Cir Esp (Engl Ed) 2021:S2173-5077(21)00209-X. [PMID: 34332915 DOI: 10.1016/j.cireng.2021.07.009] [Reference Citation Analysis]
350 Sakellariou G, Schiepatti A, Scalvini D, Lusetti F, Fazzino E, Biagi F, Montecucco C. Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Front Med 2022;9:919521. [DOI: 10.3389/fmed.2022.919521] [Reference Citation Analysis]
351 Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP, Chen MH. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut 2021;70:85-91. [PMID: 32576641 DOI: 10.1136/gutjnl-2020-320789] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 70.0] [Reference Citation Analysis]
352 Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol 2021;15:891-908. [PMID: 34148466 DOI: 10.1080/17474124.2021.1940956] [Reference Citation Analysis]
353 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
354 Yu L, Hu S, Huang FC, Wu YC, Zheng XY. Evaluation of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging for predicting muscular hyperplasia/hypertrophy in Crohn's disease. Abdom Radiol (NY) 2022;47:1714-24. [PMID: 35243533 DOI: 10.1007/s00261-022-03422-7] [Reference Citation Analysis]
355 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
356 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
357 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
358 Hu AB, Tan W, Deshpande V, Ananthakrishnan AN. Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn’s Disease in Endoscopic Remission. Clinical Gastroenterology and Hepatology 2021;19:1226-1233.e1. [DOI: 10.1016/j.cgh.2020.04.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
359 Lin R, Lin W, Wang C, Dong J, Zheng W, Zeng D, Liu Y, Lin C, Jiao Z, Huang P. Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. Basic Clin Pharmacol Toxicol 2021;128:482-92. [PMID: 33150655 DOI: 10.1111/bcpt.13530] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
360 Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine. J Transl Med 2019;17:419. [PMID: 31836022 DOI: 10.1186/s12967-019-02174-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
361 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
362 Adler J, Lin CC, Gadepalli SK, Dombkowski KJ. Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease. JAMA Netw Open. 2020;3:e207378. [PMID: 32515798 DOI: 10.1001/jamanetworkopen.2020.7378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
363 Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep 2021;23:30. [PMID: 34913108 DOI: 10.1007/s11894-021-00829-y] [Reference Citation Analysis]
364 Qiu Y, Zheng Z, Liu G, Zhao X, He A. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol J 2019;7:1198-214. [PMID: 31700633 DOI: 10.1177/2050640619878998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Zhang M, Chen QD, Xu HX, Xu YM, Chen HJ, Yang BL. Association of hidradenitis suppurativa with Crohn’s disease. World J Clin Cases 2021; 9(15): 3506-3516 [PMID: 34046451 DOI: 10.12998/wjcc.v9.i15.3506] [Reference Citation Analysis]
366 Afzali A, Furtner D, Melsheimer R, Molloy PJ. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Adv Ther 2021;38:2077-93. [PMID: 33745111 DOI: 10.1007/s12325-021-01688-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
367 Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, Bossios A, Boyman O, Chaker A, Chan S, Chatzipetrou A, du Toit G, Jutel M, Kauppi P, Kolios A, Li C, Matucci A, Marson A, Bendien S, Palomares O, Rogala B, Szepfalusi Z, Untersmayr E, Vultaggio A, Eiwegger T. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy 2021;76:71-89. [PMID: 32189356 DOI: 10.1111/all.14282] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
368 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
369 Newton L, Delbecque L, Coşkun U, Symonds T, Clegg J, Hunter T. A qualitative study to explore symptoms and impacts of pediatric and adolescent Crohn's disease from patient and caregiver perspective. J Patient Rep Outcomes 2021;5:49. [PMID: 34170423 DOI: 10.1186/s41687-021-00321-1] [Reference Citation Analysis]
370 Thiriveedi M, Steuber TD, Hasan M, Baggett A. Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature. J Gen Intern Med 2021;36:2134-8. [PMID: 33855671 DOI: 10.1007/s11606-021-06781-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 LeBlanc JF, Wiseman D, Lakatos PL, Bessissow T. Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. World J Gastroenterol 2019; 25(30): 4158-4171 [PMID: 31435170 DOI: 10.3748/wjg.v25.i30.4158] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
372 Patel DB, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. Inflammatory Bowel Diseases 2021;27:1593-601. [DOI: 10.1093/ibd/izaa311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
373 Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
374 Cross RK, Herfarth H. Is There a Role for Thiopurines in IBD? Am J Gastroenterol 2018;113:1121-4. [PMID: 29946181 DOI: 10.1038/s41395-018-0175-8] [Reference Citation Analysis]
375 Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00614-5. [PMID: 34126262 DOI: 10.1016/j.cgh.2021.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Reference Citation Analysis]
377 Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71:1285-99. [PMID: 31436026 DOI: 10.1002/acr.24025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
378 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
379 Falloon K, Cohen B, Rieder F. Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply. Aliment Pharmacol Ther 2022;55:1208-9. [PMID: 35429040 DOI: 10.1111/apt.16907] [Reference Citation Analysis]
380 Resende RH, Ribeiro IB, de Moura DTH, Galetti F, Rocha RSP, Bernardo WM, Sakai P, de Moura EGH. Surveillance in inflammatory bowel disease: is chromoendoscopy the only way to go? A systematic review and meta-analysis of randomized clinical trials. Endosc Int Open 2020;8:E578-90. [PMID: 32355874 DOI: 10.1055/a-1120-8376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
381 De Felice KM. Patients Perception of Risks and Benefits of Biologic Therapy. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
382 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
383 Ratto C, Grossi U, Litta F, Di Tanna GL, Parello A, De Simone V, Tozer P, DE Zimmerman D, Maeda Y. Contemporary surgical practice in the management of anal fistula: results from an international survey. Tech Coloproctol 2019;23:729-41. [PMID: 31368010 DOI: 10.1007/s10151-019-02051-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
384 Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, Facchin S, Lorenzon G, Marchi S, Marabotto E, De Bortoli N, Savarino V, Costa F, Blandizzi C. Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. Expert Opin Biol Ther 2019;19:79-88. [PMID: 30574820 DOI: 10.1080/14712598.2019.1561852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
385 Palmese F, Del Toro R, Di Marzio G, Cataleta P, Sama MG, Domenicali M. Sarcopenia and Vitamin D Deficiency in Patients with Crohn's Disease: Pathological Conditions That Should Be Linked Together. Nutrients 2021;13:1378. [PMID: 33923948 DOI: 10.3390/nu13041378] [Reference Citation Analysis]
386 Chen G, Pedarla V, Null KD, Cazzetta SE, Khan QR, Schwartz DA. Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula. Inflamm Bowel Dis 2021:izab198. [PMID: 34525184 DOI: 10.1093/ibd/izab198] [Reference Citation Analysis]
387 Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT, Johnson D, Ng SC, Sharma V, Rubin DT, Gibson PR, Christensen B. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther 2022;56:6-27. [PMID: 35596242 DOI: 10.1111/apt.16952] [Reference Citation Analysis]
388 Chugh R, Gaidos JK. Fertility and Pregnancy in Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.012] [Reference Citation Analysis]
389 Taha-Mehlitz S, Bianco G, Coto-Llerena M, Kancherla V, Bantug GR, Gallon J, Ercan C, Panebianco F, Eppenberger-Castori S, von Strauss M, Staubli S, Bolli M, Peterli R, Matter MS, Terracciano LM, von Flüe M, Ng CKY, Soysal SD, Kollmar O, Piscuoglio S. Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis. Theranostics 2021;11:4011-29. [PMID: 33754045 DOI: 10.7150/thno.50051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
390 Kim D, Taleban S. A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. Drugs Aging 2019;36:607-24. [PMID: 31055789 DOI: 10.1007/s40266-019-00672-x] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
391 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
392 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
393 Wu S, Zeng L, Li W, Wu YT, Jing JG, Zhuang H, Wang YF. The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease. Dig Liver Dis 2022:S1590-8658(21)00896-3. [PMID: 34991975 DOI: 10.1016/j.dld.2021.12.009] [Reference Citation Analysis]
394 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
395 Daoud ND, Hashash JG, Picco MF, Farraye FA. Fecal Calprotectin from Ileostomy Output is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease. J Crohns Colitis 2021:jjab182. [PMID: 34633435 DOI: 10.1093/ecco-jcc/jjab182] [Reference Citation Analysis]
396 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
397 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
398 Sninsky J, Barnes EL. Medical Management of Aggressive Inflammatory Bowel Disease: When Is the Time to Cut Your (and the Patient's) Losses? J Laparoendosc Adv Surg Tech A 2021;31:905-10. [PMID: 34171979 DOI: 10.1089/lap.2021.0338] [Reference Citation Analysis]
399 Choi R, Lee MN, Kim K, Baek SY, Kim TJ, Hong SN, Kim YH, Lee SY. Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease. Br J Clin Pharmacol 2020;86:2302-13. [PMID: 32372428 DOI: 10.1111/bcp.14339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
400 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
401 Watanabe K, Sasaki I, Kohyama A, Suzuki H, Kobayashi M, Kajiwara T, Karasawa H, Ohnuma S, Kamei T, Unno M. Antimesenteric cutback end-to-end isoperistaltic anastomosis (Sasaki-Watanabe anastomosis) for Crohn's disease: Novel surgical technique and early results of surgical anastomotic recurrence. Ann Gastroenterol Surg 2021;5:528-37. [PMID: 34337302 DOI: 10.1002/ags3.12445] [Reference Citation Analysis]
402 Gergely M, Deepak P. Tools for the Diagnosis and Management of Crohn's Disease. Gastroenterol Clin North Am 2022;51:213-39. [PMID: 35595412 DOI: 10.1016/j.gtc.2021.12.003] [Reference Citation Analysis]
403 Inglet S, Winter B, Yost SE, Entringer S, Lian A, Biksacky M, Pitt RD, Mortensen W. Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. Ann Pharmacother 2020;54:1109-43. [DOI: 10.1177/1060028020930189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
404 Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol 2020;18:1152-1160.e1. [PMID: 31419574 DOI: 10.1016/j.cgh.2019.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
405 Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving Pharmacogenetics Into Practice: It's All About the Evidence! Clin Pharmacol Ther 2021. [PMID: 34101169 DOI: 10.1002/cpt.2327] [Reference Citation Analysis]
406 Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. Adv Ther 2020;37:2127-43. [PMID: 32193810 DOI: 10.1007/s12325-020-01276-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
407 Zhang B, Gulati A, Alipour O, Shao L. Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis 2020;14:1413-23. [PMID: 32335670 DOI: 10.1093/ecco-jcc/jjaa087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
408 Miyazu T, Ishida N, Takano R, Tamura S, Yamade M, Hamaya Y, Tani S, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission. Medicine (Baltimore) 2021;100:e26550. [PMID: 34398010 DOI: 10.1097/MD.0000000000026550] [Reference Citation Analysis]
409 Koliani-Pace JL, Siegel CA. Prognosticating the Course of Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2019;29:395-404. [PMID: 31078243 DOI: 10.1016/j.giec.2019.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
410 Gordon M, Guyatt G. Assessment of Evidence Quality in Inflammatory Bowel Disease Guidance: The Use and Misuse of GRADE. Gastroenterology 2020;159:1209-15. [PMID: 32681924 DOI: 10.1053/j.gastro.2020.06.092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
411 Langlois DK, Tolbert MK, Webb CB, Lennon EM, Flatland B, Wennogle SAJ, Block G, Jergens AE, Heilmann RM, Murray L, Wood M, Honeckman A, Webster CRL, Twedt DC, Forman M, Marsilio S, Forcada Y, Jaffey JA, Richter K, Steiner JM. Letter regarding "Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs". J Vet Intern Med 2021;35:2567-9. [PMID: 34825412 DOI: 10.1111/jvim.16303] [Reference Citation Analysis]
412 Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review. Gut Liver 2021;15:732-41. [PMID: 33361549 DOI: 10.5009/gnl20249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
413 Avila F, Caron B, Hossu G, Ambarki K, Kannengiesser S, Odille F, Felblinger J, Danese S, Choukour M, Laurent V, Peyrin-Biroulet L. Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. Dig Dis Sci 2021. [PMID: 34802092 DOI: 10.1007/s10620-021-07311-9] [Reference Citation Analysis]
414 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 269] [Article Influence: 132.5] [Reference Citation Analysis]
415 Hanscom M, Stead C, Feldman H, Marya NB, Cave D. Video Capsule Endoscopy and Device-Assisted Enteroscopy. Dig Dis Sci 2021. [PMID: 34383197 DOI: 10.1007/s10620-021-07085-0] [Reference Citation Analysis]
416 Ajabnoor SM, Thorpe G, Abdelhamid A, Hooper L. Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr 2021;60:2293-316. [PMID: 33084958 DOI: 10.1007/s00394-020-02413-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
418 Hart A, Ng SC, Watkins J, Paridaens K, Edwards JO, Fullarton JR, Sonderegger YLY, Ghatnekar O, Ghosh S. The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol 2020;33:500-7. [PMID: 32879597 DOI: 10.20524/aog.2020.0521] [Reference Citation Analysis]
419 Nguyen NH, Singh S, Sandborn WJ. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:1268-79. [PMID: 31676360 DOI: 10.1016/j.cgh.2019.10.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
420 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
421 Love BL, Finney CJ, Gaidos JKJ. Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients. J Crohns Colitis 2021;15:1279-83. [PMID: 33491047 DOI: 10.1093/ecco-jcc/jjab017] [Reference Citation Analysis]
422 Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Curr Gastroenterol Rep. 2019;21:31. [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
423 Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00299-5. [PMID: 34739863 DOI: 10.1016/S2468-1253(21)00299-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
424 Spencer NJ, Fryer AA, Farmer AD, Duff CJ. Blood test monitoring of immunomodulatory therapy in inflammatory disease. BMJ. [DOI: 10.1136/bmj.n159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Chen H, Shi J, Pan Y, Zhang Z, Fang H, Chen Y, Chen W, Cao Q. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. Adv Ther 2020;37:431-49. [PMID: 31797196 DOI: 10.1007/s12325-019-01150-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]